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CASE REPORT
Individual time course of pre- and  
postsynaptic PET imaging may improve 
differential diagnosis of Parkinson’s disease  
and multiple system atrophy: a case report
Kenji Ishibashi1*, Hirofumi Nishina2, Kiichi Ishiwata1 and Kenji Ishii1
Abstract 
Background: Many in vivo studies have shown a difference in pre- and/or postsynaptic imaging between Parkinson’s 
disease and multiple system atrophy; however, time course differences in pre- and postsynaptic imaging between 
Parkinson’s disease and multiple system atrophy have not been rigorously investigated.
Case presentation: We report serial positron emission tomography images of both dopamine transporters and 
dopamine D2 receptors, obtained from a Japanese patient with Parkinson’s disease who underwent positron emission 
tomography scanning at ages 71, 72, 74, and 75 years, and another Japanese patient with multiple system atrophy 
who underwent positron emission tomography scanning at ages 65, 66, and 67 years. Volumes-of-interest were 
placed on the striatal subregions. The percentage decreases between the first and last images showed that dopamine 
transporter availability decreased with disease progression in both patients, but that dopamine D2 receptor availabil-
ity decreased only in the patient with multiple system atrophy. A partial correlation analysis between dopamine trans-
porter and dopamine D2 receptor availability, controlling for the effects of striatal subregional differences, revealed a 
positive correlation in the patient with multiple system atrophy (r = 0.893, P = 0.0002), but no significant correlation 
in the patient with Parkinson’s disease (r = −0.036, P = 0.89).
Conclusions: The time course of pre- and postsynaptic imaging can be considerably different between Parkinson’s 
disease and multiple system atrophy, and may be useful in improving the accuracy of discrimination between Parkin-
son’s disease and multiple system atrophy.
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Background
Parkinson’s disease (PD) and multiple system atrophy 
(MSA) are neurodegenerative disorders affecting the 
nigrostriatal dopaminergic system. Imaging of presyn-
aptic neurons using positron emission tomography 
(PET) or single photon emission computed tomography 
(SPECT) with a radioligand for dopamine transport-
ers (DATs) cannot distinguish between PD and MSA, 
especially on the individual level, because both diseases 
cause neuronal degeneration in the substantia nigra (SN) 
[1, 2]. However, PET or SPECT imaging of postsynap-
tic neurons with a radioligand for dopamine D2 recep-
tors (D2Rs) can improve the accuracy of discrimination 
between PD and MSA, as D2R-expressing striatal neu-
rons tend to degenerate in MSA but not in PD [3, 4].
Many in  vivo studies have shown a difference in pre- 
and/or postsynaptic imaging between PD and MSA 
[5–8]; however, differences in the time course of these 
measures between PD and MSA have not been rigorously 
investigated. In order to address this deficit, we examined 
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pre- and postsynaptic imaging time courses in a patient 
with PD and another with MSA, focusing on the differ-
ential diagnosis between PD and MSA. To quantify avail-
ability of DATs and D2Rs, we used carbon-11-labeled 
2β-carbomethoxy-3β-(4-fluorophenyl)-tropane (11C-




Participants comprised two Japanese female patients, one 
each with PD and MSA, who were recruited from cross-
sectional studies of PD and PD-related disorders at the 
Tokyo Metropolitan Institute of Gerontology [9]. The 
PET data used in this study were collected for research 
purposes. All procedures were approved by the Ethics 
Committee of the Tokyo Metropolitan Institute of Ger-
ontology. The two patients provided written informed 
consent for publication.
Patient with Parkinson’s disease
Six months after developing a right leg tremor, she was 
diagnosed with PD at the age of 71, and underwent 11C-
CFT and 11C-raclopride PET scanning at ages 71, 72, 74, 
and 75  years. On initial examination at age 71, she had 
resting tremor and mild rigidity of her right arm and leg. 
Levodopa was administered and effective, but without 
levodopa a mild postural instability developed at age 74. 
Her Hoehn and Yahr stage at ages 71 and 75 were 1 and 
3, respectively.
Patient with multiple system atrophy
A 65-year-old woman was referred to the neurology 
department of our hospital after she had developed a 
progressive gait disturbance over the previous 2  years. 
On initial examination, she had parkinsonian symptoms 
(postural instability, bradykinesia, and mild cogwheel 
rigidity on the left side), cerebellar ataxia, pyramidal 
sign in both legs, and orthostatic hypotension which 
was confirmed by a head-up tilt test. She was diagnosed 
with MSA, and underwent 11C-CFT and 11C-raclopride 
PET scanning at ages 65, 66, and 67  years. Levodopa 
was ineffective. Ages for aid-requiring walking, wheel-
chair dependence, and a bedridden state were 65, 66, and 
67 years, respectively.
Positron emission tomography scanning and data analysis
PET scanning was performed on a SET-2400  W scan-
ner (Shimadzu, Kyoto, Japan) in three-dimensional mode 
at the Institute. Static emission data were acquired for 
75–90  min and 40–55  min after an intravenous bolus 
infusion of 11C-CFT and 11C-raclopride, respectively. The 
injection doses for both radioligands were 300 MBq.
Volumes-of-interest (VOIs) were placed on the striatal 
subregions: the ventral striatum (VST), pre-commissural 
dorsal caudate (pre-DCA), post-commissural caudate 
(post-CA), pre-commissural dorsal putamen (pre-DPU) 
and post-commissural putamen (post-PU) [10]. A vis-
ual cortex VOI was also created and used as a reference 
region [11, 12]. To estimate DAT and D2R availability in 
each VOI, the uptake ratio index (URI) of 11C-CFT and 
11C-raclopride was calculated by the following formula: 
URI =  [(activity in the target region) −  (activity in the 
visual cortex)]/[(activity in the visual cortex)] [12]. The 
normal range for URI is different among striatal subre-
gions. In order to compare the magnitude of changes in 
DAT and D2R availability from the first to last PET images 
across striatal subregions, the Z score for each was calcu-
lated in contrast with the mean and standard deviation 
(SD) values of controls (with data belonging to the Tokyo 
Metropolitan Institute of Gerontology), as in the follow-
ing formula: Z score = [(URI in the patient) − (mean URI 
in controls)]/[(SD URI in controls)].
In order to compare the time course of pre- and post-
synaptic imaging between the patients with PD and MSA, 
we tested the relationship between DAT and D2R avail-
ability with a partial correlation approach, controlling for 
the effects of striatal subregional differences, using SPSS 
Statistics version 22 (IBM, Armonk, NY). Statistical sig-
nificance was set at P < 0.05.
Results
The Z score and percentage decreases of DAT and D2R 
availability from the first to last PET images in each stri-
atal subregion and whole striatum are shown in Fig. 1 and 
Table 1, respectively. Table 1 shows that DAT availability 
decreased with disease progression in both patients, and 
that D2R availability also decreased in the patient with 
MSA, but not the patient with PD. The partial correlation 
analysis showed a positive correlation between DAT and 
D2R availability for the patient with MSA (partial corre-
lation coefficient: r =  0.893, P =  0.0002), but there was 
no any significant correlation for the patient with PD 
(r = −0.036, P = 0.89).
The first and last DAT and D2R PET images are dis-
played in Fig. 2. Consistent with Table 1, DAT availability 
tended to decrease in both patients. However, D2R avail-
ability tended to decrease in the patient with MSA, but 
not the patient with PD.
Discussion and conclusions
Longitudinal changes in DAT and D2R imaging have 
been established in PD patents. The dorsal posterior part 
of the putamen, which is anatomically equivalent to the 
post-PU in this study, is the initial region of DAT loss and 
is most severely affected throughout the illness [2, 9, 10]. 
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The number of DATs in each subregion of the striatum 
decreases along with neuronal loss in the SN and the dis-
ease progression, presumably following an exponential 
curve [2, 10, 13]. On the other hand, according to in vitro 
studies showing that the number of striatal D2Rs is con-
stant even in the advanced stage of PD [3, 4], striatal D2R 
availability in an imaging study is also expected to be con-
stant throughout the illness. D2R images, however, may 
be complicated. In early PD, the expression of D2R may 
be upregulated as a compensatory response to a decrease 
in endogenous dopamine levels [14, 15]. In longstanding 
PD, chronic dopaminergic therapy or structural adap-
tation of the postsynaptic neurons to the progressive 
degeneration of the presynaptic dopaminergic system 
may downregulate D2R expression [16]. Additionally, the 
loss of endogenous dopamine can cause increased bind-
ing of 11C-raclopride (i.e., increased D2R availability) 
throughout the illness [17]. Our findings from an early 
PD patient were explainable based on those findings.
To our knowledge, this is the first study to investigate 
the time course of pre- and postsynaptic imaging in a 
patient with MSA, and that showed a positive correla-
tion between the two (Fig. 1). A pathological study with 
35 MSA patients has reported that neurons in both the 
SN and striatum, especially the putamen, were severely 
depleted in most cases, and that the degree of nigral 
Fig. 1 Comparison of the time course of dopamine transporter and dopamine D2 receptor availability between the patient with Parkinson’s disease 
and the patient with multiple system atrophy. Data in all striatal subregions from the first to last images were used. The horizontal and vertical 
axes represent the Z scores of dopamine transporter and dopamine D2 receptor availability, respectively. Black, blue, red, yellow, and green circles 
represent data from the ventral striatum, pre-commissural dorsal caudate, post-commissural caudate, pre-commissural dorsal putamen, and post-
commissural putamen, respectively. Open and closed circles represent the patient with Parkinson’s disease and multiple system atrophy, respec-
tively. The partial correlation, controlling for the effects of regional differences, is significant in the patient with multiple system atrophy (r = 0.893, 
P = 0.0002), but not in the patient with Parkinson’s disease (r = −0.036, P = 0.89)
Table 1 Percentage decreases of dopamine transporter and dopamine D2 receptor availability between the first and last 
positron emission tomography images
Percentage decreases were calculated by the following formula: 100 × [(uptake ratio index in the first image) − (uptake ratio index in the last image)]/(uptake ratio 
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and putaminal damage tended to be associated with dis-
ease duration [1]. The latter finding was supported by 
two neuroimaging studies (not longitudinal) showing a 
positive correlation between DAT and D2R availability 
in MSA groups [6, 12]. Together, previous and our find-
ings show that the functional impairment of both pre- 
and postsynaptic dopaminergic systems in MSA should 
develop with disease progression due to neuronal degen-
eration in the SN and striatum.
Differentiating MSA from PD is often difficult in their 
early stages, and this sometimes remains difficult even in 
the late stages of these diseases. About 20 % of patients 
still carrying a diagnosis of PD were pathologically diag-
nosed with another neurodegenerative disorder at the 
time of death, and MSA was the most frequently misi-
dentified pathology [18, 19]. Pre- and postsynaptic stri-
atal imaging can help in differential diagnosis; however, 
not all MSA patients exhibit a significant reduction of 
D2R availability [20], especially when neuronal loss in the 
striatum is mild. DAT imaging can demonstrate differ-
ences between PD and MSA on the group level but not 
on an individual level [7]. On the other hand, the present 
study showed that along with decreasing DAT availability 
(i.e., disease progression), D2R availability also decreased 
in the patient with MSA, but not in the patient with PD, 
and suggests that the time course of pre- and postsynap-
tic imaging can be considerably different between these 
conditions. Thus, in cases where initial pre- and post-
synaptic imaging cannot discriminate between PD and 
MSA, observation of the individual time courses of pre- 
and postsynaptic imaging, at an interval of at least a few 
years, may improve the differential diagnosis of PD and 
MSA. However, when pre- and postsynaptic imaging is 
used for clinical purposes, the subsequent PET or SPECT 
scans should be reserved for unclear cases and their indi-
cation should be scrutinized to avoid cumulative expo-
sure to radiation.
One of the limitations of the present study is that PD 
and MSA are heterogeneous disorders with multiple 
factors contributing to symptoms and disease progres-
sion [21, 22]. Thus, one cannot necessarily expect other 
patients with PD or MSA to follow the cases presented 
here. However, as typical cases of PD and MSA, our cases 
may provide essential information for differentiating 
between PD and MSA.
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Fig. 2 Dopamine transporter and dopamine D2 receptor images. The first and last images of dopamine transporters and dopamine D2 receptors in 
the patient with Parkinson’s disease and the patient with multiple system atrophy are displayed in axial sections. The rainbow scale represents the 
magnitude of uptake ratio index
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